Introduction: The duration of uncontrolled type 2 diabetes mellitus (T2DM) can adversely
effectively as first-line therapy in combination with metformin, as well as in patients not achieving glycemic goals with metformin therapy.
Methods: For this review, a non-systematic literature search of PubMed, NCBI, and Google Scholar was conducted.
Results: New oral agents have made it possible to improve glycemic control to near-normal levels with a low risk of hypoglycemia and without weight gain, and sometimes with weight loss. Early combination therapy is effective and has been shown to have a favorable legacy effect. A number of agents are available in a single-pill combination (SPC) that provides fewer pills and better adherence. Compared with adding a sulfonylurea, still the most common oral combination used, empagliflozin has been shown to decrease cardiovascular (CV) events in a dedicated CV outcome study, and pioglitazone has been effective in reducing the risk of secondary CV endpoints, whereas sulfonylureas have been associated with an increased risk of CV disease.
In those failing metformin, triple oral therapy by adding a non-metformin SPC such as empagliflozin/linagliptin or pioglitazone/
INTRODUCTION
Over the last several decades, the diabetes landscape has been transformed by an improved understanding of its pathophysiology and the development of an array of antihyperglycemic medications [1] . Yet, diabetes remains a pervasive disease with immense public health consequences and increasing prevalence of type 2 diabetes mellitus (T2DM) in adults [2] . Despite the number of treatment options, hyperglycemia is still often poorly controlled [3] , chiefly reflecting the limitations inherent in treatment options for T2DM and clinical inertia. Lifestyle changes such as diet or exercise are insufficient, and the efficacy of pharmacologic agents is rarely sustained over time and may be limited by side effects. After prescribing therapeutic lifestyle changes, there may be delays in initiating monotherapy, often metformin, and physicians may wait long periods of time (even years) before adding additional therapy [4] . This step-up approach is conducive to treatment failure; evidence from monotherapy studies shows that long-term glycemic control is often not durable [5, 6] . Several studies have stressed the importance of early treatment, not only to prevent small vessel disease complications, but to prevent cardiovascular (CV) events years after the completion of the trial (a result of the legacy effect) as well [7] [8] [9] .
The current therapeutic landscape also results from caution based on potential adverse events with available glucose-lowering agents [4] . For example, insulins and sulfonylureas (SUs) are associated with weight gain and hypoglycemia [1] , the latter being of particular concern in the elderly [10] . The management of T2DM may be facilitated with single-pill combinations (SPC) by enabling patients to take fewer pills per day, which may lead to improved patient adherence [11] . Many combinations include metformin and can be used early in the disease. Two other SPCs, pioglitazone/alogliptin and empagliflozin/ linagliptin, have shown good glucose-lowering efficacy when added to metformin [12, 13] .
It is important to choose agents that treat the patient as a whole, not just their hyperglycemia.
For example, individuals with T2DM are at high risk of CV disease and need aggressive therapy that includes the management of concomitant CV risk factors such as obesity, hypertension, and dyslipidemia [14] . In addition, patients with T2DM and chronic kidney disease (CKD) are also at an increased risk of severe hypoglycemia [15] and present a treatment challenge. Metformin is not recommended for use in patients with an estimated glomerular filtration rate (eGFR) less than 45 mL/min/ 1.73 2 ; however, metformin may be used safely in patients with mild impairment in kidney function and with proper monitoring in patients with moderate impairment in kidney function [16] . As the number of newly diagnosed patients with T2DM increases and patients live longer, CKD needs to be a consideration when choosing antihyperglycemic agents. In the recently published long-term follow-up to the Steno-2 trial of patients with T2DM and microalbuminuria, more intensified, multifactorial, target-driven treatment resulted in an almost 8-year longer survival with fewer CV complications [17] . Thus, a one-size-fits-all approach to treat hyperglycemia is insufficient and a patient-centered approach is necessary. Herein, we describe the rationale for early combination therapy, review the clinical efficacy and safety data for the empagliflozin/ linagliptin SPC, and discuss how SPC therapy can be used in a personalized approach. This review discusses only oral agents as they are more commonly used early in the disease. Of the nine classes of oral medications listed in Table 1 , this paper focuses on the newer classes, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium glucose cotransporter 2 (SGLT-2) inhibitors, available in the USA, as well as the older SUs and thiazolidinediones (TZDs), agents that are commonly prescribed when metformin fails. 
REVIEW METHODS
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PATHOPHYSIOLOGY
T2DM is a complex disease with multiple pathophysiologic components ( Fig. 1) .
Elevated blood glucose results from insufficient insulin production and insulin resistance, as well as a closely intertwined dysfunction of many other metabolic and hormonal pathways [18] . Impaired b cell function and impaired insulin secretion are hallmarks of T2DM. In addition, pancreatic a cells secrete inappropriately high amounts of glucagon in spite of hyperglycemia and hyperinsulinemia, the two major factors that decrease glucagon secretion and endogenous glucose production. As a result, inappropriate endogenous glucose production leads to fasting hyperglycemia and also contributes to postprandial hyperglycemia.
T2DM has evolved into a disorder that now affects a younger population afflicted with central obesity and abnormal adipocyte function [19] . In addition, the gastrointestinal tract exhibits abnormal secretion of incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide [18, 20] . These two hormones account for 90% of the incretin effect, which plays a pivotal role in maintaining normal glucose homeostasis. 
SGLT2 Inhibitors
SGLT2 inhibitors exert their effects via the kidney and their mechanism of action involves inhibiting the SGLT2 protein in the Using SPCs simplifies the treatment regimen by decreasing the number of pills and reducing the frequency of administration. Studies show that adherence is improved with administration of one tablet per day versus multiple tablets per day [76] [77] [78] [79] [80] [81] . Greater improvements in glycemic control have also been shown with an SPC versus the same medications coadministered as separate pills [77] . However, data directly addressing the effects of antihyperglycemic SPCs with respect to health care costs are quite limited [82] . Some data suggest reduced health care utilization and costs with an SPC versus loose-pill regimens [11]-a paradox as many formularies penalize SPCs with higher prices.
Prescribing an SPC limits dose flexibility, and thus many physicians prefer using them as a maintenance option rather than an initial therapy. However, the SPCs currently available for use in T2DM are formulated in a variety of dosage combinations [83] (Table 2) [85] . Despite these adverse effects, metformin remains the most commonly prescribed medication, both in monotherapy and combination [86] . SPCs are particularly useful when they can be taken once daily, and there are many fixed-dose combinations containing metformin XR (Table 2) , which also improves gastrointestinal tolerability [83] . One pill a day facilitates adherence [76] .
As with metformin, SUs have also been used extensively in SPC therapies, partly because they have been available for many years and partly because they are generic and thus relatively inexpensive. The initial SPC was a combination of metformin and an SU. It was followed by an SU combined with a TZD, now also available in a generic form ( [88] . In this trial, however, the empagliflozin 25 mg/linagliptin 5 mg SPC was not significantly better than empagliflozin 25 mg alone. When compared with linagliptin 5 mg alone, both SPC doses significantly reduced HbA1c, suggesting that without metformin the glucose reduction is mostly driven by empagliflozin [88] . Body weight reductions with the SPCs were also similar to empagliflozin alone, as were systolic BP reductions from baseline (2.1-2.5 mmHg) and a low incidence of hypoglycemia.
In both of these trials, events consistent with urinary tract infections occurred at comparable rates across all groups (10-16%), and events consistent with genital infection were present in 2-8.5% of patients, mostly women. In summary, the empagliflozin/linagliptin SPC is well tolerated, may cause a modest weight loss with lower systolic BP, and has a low rate of hypoglycemia. empagliflozin. Both combinations contain DPP-4 inhibitors, which are associated with weight neutrality. However, when used in combination, linagliptin/empagliflozin is associated with weight loss due to the SGLT2 component, and alogliptin/pioglitazone is associated with weight gain due to the TZD component. These combinations are associated with a low risk of hypoglycemia (except when used in conjunction with insulin or insulin secretagogues). Neither combination has been studied in a dedicated CV outcomes trial.
Pioglitazone/Alogliptin SPC
Several CV outcomes trials have been completed for the individual glucose-lowering agents. CV outcomes trials for sitagliptin, saxagliptin, and alogliptin have shown no increased risk of overall CV events. EMPA-REG OUTCOME is the only trial that has demonstrated that adding empagliflozin causes a reduction in major adverse CV events, all-cause mortality, CV mortality, and heart failure, as well as an improvement in renal outcomes, when compared to treatment placebo on top of the current recommended standard of care [42, 43] . In a post hoc analysis pioglitazone has also been found to have favorable CV outcomes when used for secondary intervention when compared to placebo [69, 70] . In summary, we now have different choices in the selection of oral agents available for management of hyperglycemia.
While the treatment choice needs to be patient-centered, we now have medications that in addition to glycemic control also reduce CV outcomes. 
